Final - February 23, 2022

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention Atlanta, Georgia 30329 February 23-24, 2022

Wednesda	y, February 23, 2022	
10:00	Welcome & Introductions	Dr. Grace Lee (ACIP Chair) Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
10:20	Tickborne Encephalitis (TBE) Vaccine	
	Introduction	Dr. Katherine Poehling (ACIP WG Chair)
	Review of considerations for use of TBE vaccine in travelers and	Dr. Susan Hills (CDC/NCEZID)
	laboratorians	
	Proposed recommendations	Dr. Susan Hills (CDC/NCEZID)
11:15	Cholera Vaccine	
	Introduction	Dr. Pablo Sanchez (ACIP, WG Chair)
	Clinical considerations for use of cholera vaccine in children and	Dr. Jennifer Collins (CDC/NCEZID)
	adolescents aged 2–17 years	
	Proposed recommendations	Dr. Jennifer Collins (CDC/NCEZID)
11:50	Break	
12:10	Influenza Vaccine	
	Introduction	Dr. Keipp Talbott (ACIP, WG Chair)
	Influenza activity update	Dr. Lisa Grohskopf (CDC/NCIRD)
	Recommending enhanced seasonal influenza vaccines in adults age 65 and olderpotential impacts on influenza burden	Dr. Sinead Morris (CDC/NCIRD)
	Influenza vaccines for older adults	Dr. Lisa Grohskopf (CDC/NCIRD)
1:10	Hepatitis Vaccine	
	Introduction	Dr. Kevin Ault (ACIP, WG Chair)
	PREHEVBRIO for adult HepB vaccination: EtR and GRADE	Dr. Mark Weng (CDC/NCHHSTP)
1:40	Break	
1:55	MMR Vaccine Workgroup	
	Introduction	Ms. Lynn Bahta (ACIP, WG Chair)
	MMR safety and immunogenicity	Dr. Remon Abu-Elyazeed (GSK)
2:25	Public Comment	
2:45	<u>VOTE</u>	
	TBE Vaccine	Dr. Susan Hills (CDC/NCEZID)
	Cholera Vaccine	Dr. Jennifer Collins (CDC/NCEZID)
4:00	Adjourn	
Thursday, I	February 24, 2022	
10:00	Welcome & Introductions	Dr. Grace Lee (ACIP Chair) Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
10:10	Agency Updates	
	CDC, CMS, FDA, HRSA, HIS, OIDP, NIH	
10:25	Pneumococcal Vaccines	
	Introduction	Dr. Katherine Poehling (ACIP, WG Chair)
	Epidemiology of pneumococcal disease and pneumococcal vaccine	Mr. Ryan Gierke (CDC/NCIRD)
	coverage in US children	
	PCV15 Phase 2/3 study results in children	Dr. Natalie Banniettis (Merck)
	GRADE and EtR for PCV15 use in U.S. children	Ms. Jennifer Farrar (CDC/NCIRD)
	Summary and next steps	Dr. Miwako Kobayashi (CDC/NCIRD)
12:15	Adjorn	

Final - February 23, 2022

Acronyms	
CDC	Centers for Disease Control and Prevention
CMS	Centers for Medicare and Medicaid Services
COVID-19	Coronavirus disease 2019
EtR	Evidence to Recommendations Framework
FDA	Food and Drug Administration
GRADE	Grading of Recommendations Assessment, Development and Evaluation
HRSA	Health Resources and Services Administration
IHS	Indian Health Service
NCHHSTP	National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]
NCIRD	National Center for Immunization & Respiratory Diseases [of CDC/OID]
NCEZID	National Center for Emerging and Zoonotic Diseases [of CDC/OID]
NIAID	National Institute of Allergy and Infectious Diseases
OIDP	Office of Infectious Disease and HIV/AIDS Policy
SARS-CoV-2	Severe Acute Respiratory Syndrome Coronavirus 2
WG	Work Group
WHO	World Health Organization
VE	Vaccine Effectiveness